Possibility of Predicting Serotonin Transporter Occupancy From the In Vitro Inhibition Constant for Serotonin Transporter, the Clinically Relevant Plasma Concentration of Unbound Drugs, and Their Profiles for Substrates of Transporters
- PMID: 28501470
- DOI: 10.1016/j.xphs.2017.05.007
Possibility of Predicting Serotonin Transporter Occupancy From the In Vitro Inhibition Constant for Serotonin Transporter, the Clinically Relevant Plasma Concentration of Unbound Drugs, and Their Profiles for Substrates of Transporters
Abstract
Accurate prediction of target occupancy facilitates central nervous system drug development. In this review, we discuss the predictability of serotonin transporter (SERT) occupancy in human brain estimated from in vitro Ki values for human SERT and plasma concentrations of unbound drug (Cu,plasma), as well as the impact of drug transporters in the blood-brain barrier. First, the geometric means of in vitro Ki values were compared with the means of in vivo Ki values (Ki,u,plasma) which were calculated as Cu,plasma values at 50% occupancy of SERT obtained from previous clinical positron emission tomography/single photon emission computed tomography imaging studies for 6 selective serotonin transporter reuptake inhibitors and 3 serotonin norepinephrine reuptake inhibitors. The in vitro Ki values for 7 drugs were comparable to their in vivo Ki,u,plasma values within 3-fold difference. SERT occupancy was overestimated for 5 drugs (P-glycoprotein substrates) and underestimated for 2 drugs (presumably uptake transporter substrates, although no evidence exists as yet). In conclusion, prediction of human SERT occupancy from in vitro Ki values and Cu,plasma was successful for drugs that are not transporter substrates and will become possible in future even for transporter substrates, once the transporter activities will be accurately estimated from in vitro experiments.
Keywords: P-glycoprotein; PET; blood-brain barrier; central nervous system; passive diffusion/transport.
Copyright © 2017 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor.Int J Neuropsychopharmacol. 2014 Dec 13;18(2):pyu027. doi: 10.1093/ijnp/pyu027. Int J Neuropsychopharmacol. 2014. PMID: 25522383 Free PMC article.
-
Neurotransmitter transporter occupancy following administration of centanafadine sustained-release tablets: A phase 1 study in healthy male adults.J Psychopharmacol. 2023 Feb;37(2):164-171. doi: 10.1177/02698811221140008. Epub 2022 Dec 14. J Psychopharmacol. 2023. PMID: 36515395 Free PMC article. Clinical Trial.
-
Prediction of human serotonin and norepinephrine transporter occupancy of duloxetine by pharmacokinetic/pharmacodynamic modeling in the rat.J Pharmacol Exp Ther. 2012 Apr;341(1):137-45. doi: 10.1124/jpet.111.188417. Epub 2012 Jan 10. J Pharmacol Exp Ther. 2012. PMID: 22235148
-
PET Studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS.Curr Pharm Des. 2004;10(13):1493-503. doi: 10.2174/1381612043384736. Curr Pharm Des. 2004. PMID: 15134571 Review.
-
[Molecular imaging in the drug development of psychotropics using positron emission tomography].Brain Nerve. 2007 Mar;59(3):215-20. Brain Nerve. 2007. PMID: 17370647 Review. Japanese.
Cited by
-
Differentiated HT22 cells as a novel model for in vitro screening of serotonin reuptake inhibitors.Front Pharmacol. 2023 Jan 10;13:1062650. doi: 10.3389/fphar.2022.1062650. eCollection 2022. Front Pharmacol. 2023. PMID: 36703746 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical